Oseltamivir (Tamiflu)

02/01/2013 - "Most of the available studies indicate that oseltamivir use, whether therapeutic or prophylactic, is effective in containing influenza outbreaks in those settings though there are some reports of moderately high side effects, particularly among young children. "
01/01/2016 - "Because the vaccine remains the best option for preventing influenza and its complications, prophylaxis using oseltamivir should only be considered in select patients. "
08/01/2015 - "Furthermore, multiple strains of influenza virus that were resistant to oseltamivir, an FDA-approved therapeutic treatment for influenza, were highly sensitive to inhibition by M8. "
07/01/2009 - "Therefore, the in vivo efficacy of oseltamivir against highly pathogenic H5N1 influenza viruses cannot be reliably predicted by susceptibility testing, and more prognostic ways to evaluate anti-influenza compounds must be developed. "
06/01/2009 - "Although all three methods were effective in detecting the H275Y mutation associated with oseltamivir resistance, the H275Y RT-PCR assay was the most rapid and could easily be incorporated into an influenza subtyping protocol."

01/01/2007 - "Oseltamivir produced a dose-dependent effect against both recombinant H5N1 viruses (P < 0.05) but did not provide complete protection against lethal infection. "
02/01/2011 - "Many observational studies indicate that oseltamivir treatment is associated with symptomatic improvement in pediatric patients with H1N1 infection and, therefore, is considered to represent a viable therapeutic option for use in children. "
12/01/2015 - "Echinaforce Hotdrink is as effective as oseltamivir in the early treatment of clinically diagnosed and virologically confirmed influenza virus infections with a reduced risk of complications and adverse events. "
01/01/2009 - "Oseltamivir phosphate, which is available in oral formulation, is effective for type A/B influenza virus infection. "
03/01/2007 - "Oseltamivir (20 mg/kg/day), administered per os twice daily for 5 days, was tested in parallel in two experiments; it was only weakly effective against the infection. "

06/01/2010 - "Oseltamivir was effective in shortening the duration of fever in patients with temperature higher than 39°C."
01/01/2012 - "The average duration of the fever in the group of ergoferon was 2.3 +/- 1.2 days, in the group of oseltamivir--2.6 +/- 1.3 days (the efficacy of oseltamivir in the present study was comparable with the previously published data). "
01/01/2014 - "Fever alleviation time was 2.5 and 5 hours in CHDI and oseltamivir, respectively, and fever clearance time was 32.5 and 49 hours. "
08/01/2012 - "Almost all (98%) patients had fever, 53 (87%) patients received oseltamivir treatment and 51% of them received oseltamivir within 48 hours. "
04/01/2012 - "Fever and other symptoms were noticeably prolonged after oseltamivir therapy for children with H275Y mutated seasonal H1N1 (2008-2009 season), but not in patients with seasonal H1N1 without mutation (2007-2008) or H1N1pdm (2009-2010). "

07/01/2007 - "Avian influenza A viruses in birds of the order Psittaciformes: reports on virus isolations, transmission experiments and vaccinations and initial studies on innocuity and efficacy of oseltamivir in ovo."
12/01/2011 - "Antiviral efficacy of oseltamivir against avian influenza virus in avian species."
03/01/2012 - "This study showed that oseltamivir-resistant N6 NA avian influenza viruses are rare, and must be tested both phenotypically and genotypically to confirm resistance."
05/01/2011 - "Study of specific oligosaccharide structures related with swine flu (H1N1) and avian flu, and tamiflu as their remedy."
08/01/2015 - "Pyrosequencing reveals an oseltamivir-resistant marker in the quasispecies of avian influenza A (H7N9) virus."

08/01/2012 - "A high dose (10 mg/kg) of oseltamivir initiated at 24 h p.i. also prevented mortality and significantly decreased weight loss (P < 0.05) and LVT (P < 0.001) compared to the untreated group results. "
02/01/2012 - "Balb/c mice were infected with mouse-adapted pandemic influenza virus A/California/07/09 (H1N1)v. Mortality, weight loss, infectious titer of the virus in lungs and lung morphology were monitored in the groups of AC®-, oseltamivir- and placebo-treated animals. "
02/01/2010 - "While a clear advantage to the use of oseltamivir was not established, a significant weight loss during hospitalization, as well as a significant decrease in WBC count were documented in the control group. "
03/01/2007 - "Oseltamivir treatment decreased RSV-induced weight loss and inhibited RSV clearance. "
01/01/2011 - "TheraMax (combined directly with virus) and oseltamivir each prevented death and curtailed weight loss during the infection, and improved lung haemorrhage scores on day 6. TheraMax starting at -2 h or 12 h significantly delayed death by >2 days and reduced lung haemorrhage scores, but most animals died. "